Inclusion Criteria:

- Adult patients, >/= 18 years of age

- Histologically or cytologically confirmed locally advanced or metastatic non-small
cell lung cancer (NSCLC)

- Patients with known wild-type EGFR gene; patients with unknown EGFR mutation status
are allowed if they fulfil the following criteria:

- squamous cell carcinoma lung cancer histology, and

- current smoker, or former smoker who has stopped smoking less than 10 years ago and
has had a total of >15 pack-years of smoking

- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2

- Patients having failed one prior chemotherapy regimen and eligible for a second-line
treatment with Tarceva

Exclusion Criteria:

- Current treatment with an investigational drug or participation in another
investigational study

- Severe or uncontrolled systemic disease, active infection, concomitant malignancy or
a second primary malignancy except for in situ carcinoma of the cervix or adequately
treated basal cell carcinoma of the skin

- Clinically active interstitial lung disease

- Recent myocardial infarction or unstable angina

- Progressive or uncontrolled brain metastases